NCT04869358View on ClinicalTrials.gov

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

May 10, 2022

Study Completion Date

June 13, 2023

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Ofatumumab

Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter

Trial Locations (6)

13353

Novartis Investigative Site, Berlin

57076

Novartis Investigative Site, Siegen

64711

Novartis Investigative Site, Erbach im Odenwald

82008

Novartis Investigative Site, Unterhaching

D 33647

Novartis Investigative Site, Bielefeld

01307

Novartis Investigative Site, Dresden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY